How the microbiome-gut-brain axis impacts social cognition and craving in young binge drinkers

The study reveals a connection between gut microbiome changes and the most prevalent form of alcohol misuse in adolescence, occurring even before the onset of addiction.

How does Probi® Osteo work?

Watch the mode of action video to understand how this solution works to positively affect the natural balance between bone formation and bone resorption.

MicrobiotaMi 2023 highlights

Maria Rescigno, professor at Humanitas University, discusses with MicrobioomePost what emerged at MicrobiotaMI congress 2023.

Immune cells may shuttle beneficial gut microbes to boost anticancer responses

The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.

Babies receive microbes from their mothers through multiple routes

The findings of a new study suggest that mothers transmit bacteria to their infants through multiple routes — a process that ensures that babies receive essential microbes.

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® in a Phase 1b Clinical Trial in Melanoma

The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.

Microbial therapeutics market: Sacco System launches ‘Microbiome’, the suite of active ingredients and services

Marco Caspani, Executive Director of the Microbiome Division of Sacco System, explains how the company is directing his efforts and strong focus to the field of Biotherapeutics with the launch of…

A gut microbe can promote growth in mice

The findings of a new study suggest that providing at-risk populations with NOD2 ligands or probiotic bacteria that release high levels of NOD2-activating molecules may help to treat undernutrition.

Microbiota-derived metabolite may help combat pancreatic cancer

The findings of a new study suggest that the microbial metabolite 3-IAA could help to treat PDAC.

Scioto Biosciences announces publication of Phase 1b study in autism

The first-in-human study double-blind, placebo controlled, 28-day crossover study of the safety and tolerability of SB-121

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top